Skip to main content
logo
SymBio Pharmaceuticals Limited (TYO:4582)
Japan flag Japan · Delayed Price · Currency is JPY
69.00
+3.00 (4.55%)
Jul 31, 2026, 3:30 PM JST

SymBio Pharmaceuticals Financials Overview

Millions JPY. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1,2771,3072,4525,58910,0088,257
Revenue Growth
-39.73%-46.70%-56.13%-44.16%21.21%176.42%
Gross Profit
917.769471,8734,4107,6005,804
Operating Income
-5,613-4,441-3,877-8121,9641,016
Net Income
-5,856-4,776-3,833-1,9621,1792,032
Earnings Per Share
-106.24-95.12-84.99-49.1729.7752.32
EPS Growth
-----43.10%-

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,8982,8833,9636,5176,2823,860
Total Debt
1,0281,982----
Net Cash (Debt)
870.429013,9636,5176,2823,860
Net Cash Growth
-70.14%-77.27%-39.19%3.74%62.74%0.30%
Net Cash Per Share
15.7917.9487.88163.32158.6299.38

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
--4,575-3,416-1941,614140.04
Capital Expenditures
---19-204-2-25.45
Free Cash Flow
--4,575-3,435-3981,612114.59
Free Cash Flow Growth
----1306.78%-

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
71.86%72.46%76.39%78.91%75.94%70.30%
Operating Margin
-439.49%-339.79%-158.12%-14.53%19.62%12.31%
Pretax Margin
-456.22%-363.35%-155.26%-21.38%21.04%12.13%
Profit Margin
-458.55%-365.42%-156.32%-35.10%11.78%24.61%
FCF Margin
--350.04%-140.09%-7.12%16.11%1.39%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
----21.5421.62
P/FCF Ratio
----15.76383.47
PS Ratio
3.903.843.721.872.545.32